Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335452 · ClinicalTrials.gov registry record · Phase 3
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 25,086
- Enrollment target
NCT00335452 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 25,086 participants.
The verdict
NCT00335452, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25,086 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).
Interventions
- DRUG Clopidogrel
- DRUG acetylsalicyclic acid (ASA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,086 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335452
The ClinicalTrials.gov registry entry for NCT00335452 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25,086 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT00335452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335452 about?
NCT00335452 is a clinical study titled "Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS". The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).
What is the current status of trial NCT00335452?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25,086 participants. The study started on 2006-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00335452?
The interventions under investigation include: Clopidogrel (DRUG), acetylsalicyclic acid (ASA) (DRUG).
Who is sponsoring clinical trial NCT00335452?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.